- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07947849
Efficacy of Postbiotic Supplementation in Improving Antioxidant Status
Effects of Postbiotic Supplementation in Improving Total Antioxidant Status in Healthy Adults
This study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being during eight weeks of postbiotic supplementation in generally healthy adults.
Thirty-six participants aged 18 years or older will receive MettaBion Liquid twice daily for eight weeks. Assessments will be conducted before supplementation and at Weeks 4 and 8. Saliva samples will be analysed for total antioxidant capacity, malondialdehyde, 3-nitrotyrosine, and 8-hydroxy-2'-deoxyguanosine. General well-being will be assessed using a visual analogue scale.
This prospective, single-arm study will estimate within-participant changes and their variability to inform the design and sample-size planning of a future randomised, placebo-controlled trial.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This prospective, single-arm, open-label study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being following eight weeks of postbiotic supplementation in generally healthy adults. The study will recruit 36 participants aged 18 years or older. Assessments will be conducted at baseline, Week 4, and Week 8.
Participants will consume MettaBion Liquid orally for eight weeks, taking one sachet after breakfast and one sachet after dinner each day. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum, providing a total daily intake of 10,000 mg of the preparation. Adherence will be monitored using a participant compliance form.
Unstimulated saliva samples will be collected at each assessment visit to measure total antioxidant capacity (T-AOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) using Elabscience assay kits. These measurements will assess antioxidant capacity and markers of lipid peroxidation, protein nitration, and oxidative DNA damage, respectively. Participants will also assess their general well-being using a visual analogue scale ranging from 1 to 10, with higher scores indicating better perceived well-being.
The primary outcome will be the change in salivary T-AOC from baseline to Week 8. Secondary outcomes will include the change in salivary T-AOC from baseline to Week 4 and changes in salivary MDA, 3-NT, 8-OHdG, and general well-being scores from baseline to Weeks 4 and 8.
Eligible participants must be generally healthy, willing to follow the study procedures and attend follow-up visits, and able to provide written informed consent before enrolment. Individuals will be excluded if they are currently taking supplements intended to improve antioxidant status, antibiotics, antiviral medicines, or prebiotic or postbiotic supplements; have undergone major surgery within the preceding six months; or are pregnant or breastfeeding.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Chung Keat Tan, PhD
- Telefonnummer: +6017-5063305
- E-Mail: cktan.jsci@gmail.com
Studienorte
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malaysia, 56000
- UCSI University
-
Kontakt:
- Eugenie Sin Sing Tan, PhD
- Telefonnummer: +6016-8924008
- E-Mail: eugenietan@ucsiuniversity.edu.my
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Generally healthy adults aged 18 years or older.
- Willing to follow the study plan and attend follow-up visits.
- Willing to provide written informed consent before enrolment.
Exclusion Criteria:
- Currently taking supplements intended to improve antioxidant status.
- Currently taking antibiotics or antiviral medicines.
- Currently taking prebiotic or postbiotic supplements.
- Major surgery within the previous six months.
- Pregnant or breastfeeding.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: MettaBion Liquid Supplementation
Participants will consume one sachet of MettaBion Liquid after breakfast and one sachet after dinner daily for eight weeks. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in salivary total antioxidant capacity from baseline to Week 8
Zeitfenster: Baseline and Week 8
|
Change in salivary total antioxidant capacity measured using an Elabscience assay kit. |
Baseline and Week 8
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in salivary malondialdehyde
Zeitfenster: Baseline and Week 8
|
Change in salivary malondialdehyde, a marker of lipid peroxidation, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Change in salivary 3-nitrotyrosine
Zeitfenster: Baseline and Week 8
|
Change in salivary 3-nitrotyrosine, a marker of protein nitration, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Salivary 8-hydroxy-2'-deoxyguanosine (8-OHdG)
Zeitfenster: Baseline and Week 8
|
Change in salivary 8-hydroxy-2'-deoxyguanosine, a marker of oxidative DNA damage, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Self-perceived general well-being
Zeitfenster: Baseline, Week 4, and Week 8
|
Change in self-perceived general well-being assessed using a visual analogue scale ranging from 1 to 10, with higher scores indicating better general well-being. |
Baseline, Week 4, and Week 8
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- METTABION - ANTIOXIDANT
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
De-identified individual participant data underlying the published results will be made available to qualified researchers upon reasonable request to the principal investigator. Access will be subject to review of the proposed research purpose, consistency with participant consent and institutional ethics requirements, and a signed data use agreement.
IPD-Sharing-Zeitrahmen
Beginning six months after publication of the study results and continuing for five years.
IPD-Sharing-Zugriffskriterien
Researchers must submit a methodologically sound proposal outlining the intended use of the data to the principal investigator.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .